Stock MRKR MARKER THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
4.98 USD +0.61% Intraday chart for Marker Therapeutics, Inc. -4.05% -9.45%
Jul. 01 Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index CI
Jul. 01 Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Index
CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Index
CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell Microcap Growth Index
CI
Marker Therapeutics, Inc.(NasdaqCM:MRKR) added to Russell 3000E Growth Index
CI
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M
MT
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
AQ
Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target
MT
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
AQ
North American Morning Briefing : Stocks Edge -2-
DJ
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
AQ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
AQ
North American Morning Briefing : Markets on Hold -2-
DJ
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
AQ
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
AQ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601
CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
AQ
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
CI
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRKR Stock
  4. News Marker Therapeutics, Inc.